Israeli research has found that the South African variant of the new coronary pneumonia (COVID-19) virus can, to some extent, “break through” the protective power of Pfizer’s and BioNTech’s vaccines. Photo: Reproduced from Pfizer’s Facebook page
Recently, Israeli research found that the South African variant of New Coronary Pneumonia (COVID-19) could “break through” the protective power of the Pfizer and BioNTech vaccines to a certain extent, but this study has not been reviewed by the academic community. The study has not yet been reviewed by the academic community.
According to Reuters, researchers surveyed nearly 400 patients who were infected with New Coronary Pneumonia 14 days after receiving one or two doses of Pfizer vaccine and compared them to the same number of unvaccinated and confirmed patients. 0.7 percent, respectively.
Adi Stern, an expert at Tel Aviv University, said this means that the South African variant is able to break through the protection of the Pfizer vaccine to some extent. The team also revealed that it was clear that the Pfizer vaccine was less protective against the South African variant compared to the British variant. However, some past studies have shown that the Pfizer and BioNTech vaccines provide a strong defense against the South African variant, although less protection than against other variants.
The researchers emphasized that the study was conducted on a small sample of patients with the South African variant and that the subjects were all diagnosed patients, so no inferences can be drawn about the overall infection rate of the variant or the overall effectiveness of the vaccine.
Stern also said that although the results of this study may be of concern, the prevalence of South African variola virus is not high and has not spread widely in the population.
Recent Comments